In a patient on chronic warfarin who presents with moderate hematuria and glucosuria (urine glucose 500 mg/dL) without a prior diabetes diagnosis, what are the appropriate outpatient management steps?

Outpatient Management of Warfarin-Associated Hematuria with Glucosuria

In a patient on chronic warfarin presenting with moderate hematuria and significant glucosuria (500 mg/dL) without known diabetes, immediately check the INR and hold warfarin if INR >3.0, while simultaneously initiating evaluation for new-onset diabetes and pursuing urologic workup for the hematuria. 1

Immediate Assessment and Stabilization

Step 1: Check INR and Assess Bleeding Severity

• Obtain stat INR - warfarin-related nephropathy occurs with INR >3.0 due to glomerular bleeding 2
• Assess hemodynamic stability (blood pressure, heart rate, orthostatic changes)
• Check hemoglobin/hematocrit to quantify blood loss
• If INR >3.0-5.0 without active bleeding: Hold 1-2 doses of warfarin and resume at lower dose when INR therapeutic 3
• If INR >5.0: Consider low-dose oral vitamin K (1-2.5 mg) in addition to holding warfarin 3

Step 2: Evaluate for New-Onset Diabetes

The glucosuria of 500 mg/dL is highly abnormal and requires immediate investigation:

• Check fasting plasma glucose or random glucose - if random glucose ≥200 mg/dL with symptoms, diabetes is confirmed 4
• Obtain HbA1c - if ≥6.5%, confirms diabetes diagnosis 4
• Check basic metabolic panel (BUN, creatinine, electrolytes) to assess for diabetic ketoacidosis or hyperosmolar state 5
• Assess for symptoms: polyuria, polydipsia, weight loss, blurred vision
• If glucose >250 mg/dL with ketones or symptoms of DKA/HHS, this becomes an emergency requiring immediate hospitalization 5

Critical caveat: The combination of warfarin and potential new diabetes creates a drug interaction concern - initiating glucose-lowering medications (particularly metformin) can reduce warfarin efficacy and lower INR 6, requiring closer INR monitoring.

Step 3: Characterize the Hematuria

Urinalysis with Microscopy

• Quantify RBCs per high-power field - moderate hematuria suggests >25 RBCs/HPF
• Assess RBC morphology:
  • Dysmorphic RBCs suggest glomerular source (glomerulonephritis) 7, 8
  • Isomorphic RBCs suggest urologic source (tumor, stones, infection)
• Check for proteinuria - albumin-to-creatinine ratio (UACR) 8
• Look for white blood cells/bacteria (infection)
• The presence of both hematuria and glucosuria without proteinuria makes glomerular disease less likely 7

Risk Stratification for Malignancy

According to the 2020/2025 AUA/SUFU guidelines, this patient requires high-risk evaluation based on: 9, 10

• Moderate hematuria (not just microscopic)
• Chronic anticoagulation (though this is a confounding factor)
• Need to assess additional risk factors: age >35, smoking history, occupational exposures, prior pelvic radiation 11, 9

Important distinction: While anticoagulation can cause hematuria, up to 24-25% of patients on warfarin with gross hematuria have urologic malignancy 12, 13, and excessive anticoagulation should not impede full evaluation 12.

Step 4: Coordinate Urologic Evaluation

Imaging

• CT urography without and with contrast is the preferred initial imaging for high-risk hematuria 11
• If CT contraindicated (renal insufficiency from new diabetes), consider:
  • Renal ultrasound to assess kidney size, masses, hydronephrosis
  • MR urography as alternative 11

Cystoscopy

• Refer to urology for cystoscopy - indicated for all patients with moderate/gross hematuria at high risk 9
• Can be performed as outpatient procedure
• Do not delay cystoscopy due to anticoagulation - the diagnostic yield is too important 12, 13
• Cystoscopy can typically be performed safely with INR 2.0-3.0; coordinate timing with INR normalization if elevated

Step 5: Warfarin Management During Evaluation

Balancing Thrombotic vs Bleeding Risk

• Determine indication for warfarin: atrial fibrillation, mechanical valve, VTE history
• High thrombotic risk (mechanical mitral valve, recent VTE <3 months): Consider bridging with heparin if warfarin must be held >48 hours 3
• Low-moderate thrombotic risk (atrial fibrillation without prior stroke, remote VTE): Can hold warfarin 3-5 days before procedures 3

Monitoring Plan

• Check INR every 2-3 days while adjusting warfarin dose 3
• Once stable, can extend to weekly then monthly monitoring
• More frequent monitoring required when initiating diabetes medications due to drug interaction 6

Step 6: Diabetes Management Initiation

If Diabetes Confirmed (HbA1c ≥6.5% or FPG ≥126 mg/dL):

First-line therapy considerations with warfarin interaction in mind:

1. Metformin - preferred initial agent 14

   • Start 500 mg daily with meals, titrate gradually
   • Critical interaction: Metformin initiation reduces warfarin effect and lowers INR 6
   • Increase INR monitoring to twice weekly for first 2-4 weeks after starting metformin
   • May need to increase warfarin dose by 10-20%
   • Check renal function first - if eGFR <45, reduce dose; if <30, contraindicated 14

2. Consider SGLT2 inhibitor if eGFR >20 mL/min/1.73 m² 14

   • Provides cardiovascular and renal protection
   • Less drug interaction concern with warfarin
   • Monitor for genital mycotic infections, volume depletion

3. Avoid sulfonylureas initially - increased hypoglycemia risk in elderly, especially with warfarin 14

Diabetes Education

• Glucose monitoring (if on medications causing hypoglycemia)
• Dietary counseling - maintain consistent vitamin K intake (green leafy vegetables) to avoid INR fluctuations 1
• Avoid cranberry products (increase warfarin effect) 1

Step 7: Follow-Up Plan

Short-term (1-2 weeks):

• Repeat INR after warfarin dose adjustment
• Review urinalysis results and imaging
• Confirm diabetes diagnosis with repeat testing if initial test borderline
• Urology consultation for cystoscopy scheduling

Medium-term (1 month):

• Mandatory follow-up after any warfarin dose changes 3
• Repeat HbA1c in 3 months to assess diabetes control
• Repeat INR 1-2 weeks after starting metformin due to drug interaction 6
• Review cystoscopy and imaging results
• Adjust diabetes medications based on glucose control

Long-term:

• Annual screening for diabetic kidney disease with UACR and eGFR 8
• Optimize blood pressure control (<130/80 mmHg) 8
• Consider ACE inhibitor or ARB if UACR ≥30 mg/g 8
• If persistent hematuria after negative workup: Repeat urinalysis in 6-12 months; if stable and benign etiology identified, can discharge from urology care after shared decision-making 9, 10

Key Pitfalls to Avoid

1. Do not assume hematuria is solely due to warfarin - 24-25% have significant pathology including malignancy 12, 13
2. Do not delay urologic evaluation waiting for INR to normalize - diagnostic yield is too important 12
3. Do not ignore the glucosuria - this represents new-onset diabetes requiring evaluation and treatment
4. Do not start metformin without planning for increased INR monitoring - significant drug interaction 6
5. Do not discharge patient without clear follow-up plan - both conditions require ongoing management
6. Do not overlook warfarin-related nephropathy - can cause AKI with INR >3.0, though usually transient 2